Log in Free sign up

Oragenics (OGEN) News and press releases

News

From Benzinga Pro

Oragenics Chair Sends Letter To Shareholders

News, Management

Oragenics, Inc. (NYSE:OGEN) (“Oragenics” or the “Company”) today issued the following letter to shareholders from its Executive Chairman, Frederick W. Telling, Ph.D.: To My Fellow

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

Biotech, Earnings, Large Cap, M&A, News, Penny Stocks, Health Care, Financing, Offerings, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours.

Earnings Scheduled For April 27, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter.

Oragenics's Earnings: A Preview

Oragenics (AMEX:OGEN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Oragenics will report an earnings per share (EPS) of $-0.02.

Oragenics Extends Collaboration To Develop Vaccines Against Future Variants Of Coronaviruses

Biotech, General

Agreement extends current licensing and collaboration agreement to include rapid production of intranasal vaccine candidates against future variants TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE:OGEN)

68 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation.

Executives Buy Around $5.5M Of 3 Penny Stocks

Long Ideas, News, Penny Stocks, Small Cap, Insider Trades, Markets, Trading Ideas

US crude oil futures traded higher on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

4 Penny Stocks Insiders Are Buying

Long Ideas, News, Penny Stocks, Insider Trades, Markets, Trading Ideas

US crude oil futures traded sharply lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Oragenics Reports Received Audit Opinion Of Going Concern Explanation

Oragenics, Inc. (NYSE:OGEN) (“Oragenics” or the “Company”) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021, which was filed on

Oragenics Initiates Pivotal IND-Enabling Toxicology Study On Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

Biotech, News, FDA, General

Data to establish the safety profile and human dose of vaccine candidate Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today announced the initiation of a Good Laboratory Practice

Oragenics Partners With KBI Biopharma To Produce Material For Its Intranasal COVID-19 Vaccine Candidate

Biotech, News, Penny Stocks, Health Care, Contracts, General

Oragenics Enters Agreement With KBI Biopharma For Process Transfer, Optimization And cGMP Manufacturing Of Co.'s Intranasal Vaccine Candidate NT-CoV2-1; KBI To Produce Material For Use In Future Expected Phase 2 Clinical Trial Of Oragenics' Vaccine

Biotech, General

KBI to produce material for use in future expected Phase 2 clinical trial of Oragenics' intranasal vaccine candidate TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE:OGEN) (“Oragenics” or the

Oragenics Announces Posting Of Preprint Manuscript On Data For Intranasal SARS-CoV-2 Vaccine Candidate

Biotech, News, Penny Stocks, FDA, General

Intranasal Immunization Lowers the Viral Load Below the Limit of Detection in Lungs of Hamsters Oragenics, Inc. (NYSE: OGEN) ("Oragenics" or the "Company") today announced the posting of aIntranasal Immunization Lowers the Viral Load Below the Limit of Detection in Lungs of Hamsters

Press releases

From Benzinga Pro

Oragenics Issues Letter to Shareholders

Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today issued the following letter to shareholders from its Executive Chairman, Frederick W. Telling, Ph.D.: To My Fellow Shareholders, I am pleased to share

Oragenics to Participate at the World Vaccine Congress Washington 2022

Company to showcase NT-CoV2-1, a patient-friendly Covid vaccine candidate Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronavirus,

Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses

Agreement extends current licensing and collaboration agreement to include rapid production of intranasal vaccine candidates against future variants Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021, which was filed on March 24, 2022 with the

Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

Data to establish the safety profile and human dose of vaccine candidate Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today announced the initiation of a Good Laboratory Practice (GLP) toxicology study to

Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

KBI to produce material for use in future expected Phase 2 clinical trial of Oragenics' intranasal vaccine candidate Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today announced it has entered into an

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Intranasal Immunization Lowers the Viral Load Below the Limit of Detection in Lungs of Hamsters Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today announced the posting of a preprint manuscript in bioRxiv